Isokotomolide A, a new butanolide extracted from the leaves of Cinnamomum kotoense, arrests cell cycle progression and induces apoptosis through the induction of p53/p21 and the initiation of mitochondrial system in human non-small cell lung cancer A549 cells

European Journal of Pharmacology

Volumn 574, Issue 2-3, 2007, Pages 94-102

  Chen, Chung Yi ^a   Hsu, Ya Ling ^b   Chen, Yin Yi ^b   Hung, Jen Yu ^c   Huang, Ming Shyan ^c   Kuo, Po Lin ^b  

^a FOOYIN UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Cell cycle; Isokotomolide A; Lung cancer; Mitochondria; p53

Indexed keywords

BUTYROLACTONE; CASPASE 9; CASPASE 9 INHIBITOR; CINNAMOMUM KOTOENSE EXTRACT; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYTOCHROME C; ISOKOTOMOLIDE A; PLANT EXTRACT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CINNAMOMUM; CINNAMOMUM KOTOENSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOCHONDRION; PLANT LEAF; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

4-BUTYROLACTONE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35348858896     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.07.028     Document Type: Article

References (33)

1. Adhami V.M., Aziz M.H., Reagan-Shaw S.R., Nihal M., Mukhtar H., and Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol. Cancer Ther. 3 (2004) 933-940
2. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
3. Buschmann T., Adler V., Matusevich E., Fuchs S.Y., and Ronai Z. p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res. 60 (2000) 896-900
4. Cao M.Y., Lee Y., Feng N.P., Al-Qawasmeh R.A., Viau S., Gu X.P., Lau L., Jin H., Wang M., Vassilakos A., Wright J.A., and Young A.H. NC381, a novel anticancer agent, arrests the cell cycle in G0-G1 and inhibits lung tumor cell growth in vitro and in vivo. J. Pharmacol. Exp. Ther. 308 (2004) 538-546
5. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., Albanese C., Sausville E.A., and Senderowicz A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59 (1999) 4634-4641
6. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., and Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cells 9 (2006) 351-365
7. Chen C.H., Lo W.L., Liu Y.C., and Chen C.Y. Chemical and cytotoxic constituents from the leaves of Cinnamomum kotoense. J. Nat. Prod. 69 (2006) 927-933
8. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 (1998) 3499-3511
9. Ferrone M., Perrone F., Tamborini E., Paneni M.S., Fermeglia M., Suardi S., Pastore E., Delia D., Pierotti M.A., Pricl S., and Pilotti S. Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). Mol. Cancer Ther. 5 (2006) 1467-1473
10. Freedman V.H., and Shin S.I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3 (1974) 355-359
11. Fuchs S.Y., Adler V., Pincus M.R., and Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10541-10546
12. Gladden A.B., and Diehl J.A. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell 4 (2003) 160-162
13. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
14. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
15. Hsu Y.L., Cho C.Y., Kuo P.L., Huang Y.T., and Lin C.C. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J. Pharmacol. Exp. Ther. 318 (2006) 484-494
16. Kasibhatla S., and Tseng B. Why target apoptosis in cancer treatment?. Mol. Cancer Ther. 2 (2003) 573-580
17. Kelly K. The role of targeted agents in adjuvant therapy for non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 5027s-5029s
18. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., and Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8 (2006) 1348-1358
19. Kramer D.L., Vujcic S., Diegelman P., Alderfer J., Miller J.T., Black J.D., Bergeron R.J., and Porter C.W. Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59 (1999) 1278-1286
20. Levesque A.A., and Eastman A. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?. Carcinogenesis 28 (2007) 13-20
21. Martin E.J., and Forkert P.G. Evidence that 1,1-dichloroethylene induces apoptotic cell death in murine liver. J. Pharmacol. Exp. Ther. 310 (2004) 33-42
22. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin. Oncol. 33 (2006) 449-456
23. Raez L.E., and Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin. Adv. Hematol. Oncol. 2 (2004) 173-178
24. Robles A.I., Linke S.P., and Harris C.C. The p53 network in lung carcinogenesis. Oncogene 21 (2002) 6898-6907
25. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
26. Shin S.I., Freedman V.H., Risser R., and Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc. Natl. Acad.Sci. U. S. A. 72 (1975) 4435-4439
27. Steinke K. Lung tumors. Recent Results Cancer Res. 167 (2006) 107-122
28. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815
29. Tyagi A., Agarwal C., and Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol. Cancer Ther. 1 (2002) 525-532
30. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. 331 (2005) 868-880
31. Waxman D.J., and Schwartz P.S. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 15 (2003) 8563-8572
32. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 10 (2003) 400-403
33. Yu Q., Geng Y., and Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411 (2001) 1017-1021